Romosozumab-aqqg (Evenity™)

Evenity (romosozumab‑aqqg) is covered only for postmenopausal women with osteoporosis at high risk for fracture (history of osteoporotic/fragility fracture or meeting BMD criteria) for up to 12 monthly 210 mg subcutaneous doses per therapy course (approval valid 12 months); use beyond 12 doses or for non‑FDA indications is not covered. Approval requires documentation of postmenopausal status and FDA‑approved indication plus fracture history or BMD T‑score ≤‑2.5 (or T‑score ‑1.0 to ‑2.5 with high fracture risk), and evidence of prior therapy failure/intolerance (≥12 months oral bisphosphonate with inadequate efficacy, significant intolerance, inability to take oral bisphosphonates, prior IV bisphosphonate trial) or severe renal impairment (CrCl <35 mL/min)/CKD.

"Treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk for fracture; or patients who have failed or are intoler..."